Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

GSK3 takes centre stage more than 20 years after its discovery.

Frame S, Cohen P.

Biochem J. 2001 Oct 1;359(Pt 1):1-16. Review.

2.

Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes.

Wagman AS, Johnson KW, Bussiere DE.

Curr Pharm Des. 2004;10(10):1105-37. Review.

PMID:
15078145
3.

Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions.

Biondi RM, Nebreda AR.

Biochem J. 2003 May 15;372(Pt 1):1-13. Review.

4.

Inhibition of GSK3 dependent tau phosphorylation by metals.

Gómez-Ramos A, Domínguez J, Zafra D, Corominola H, Gomis R, Guinovart JJ, Avila J.

Curr Alzheimer Res. 2006 Apr;3(2):123-7. Review.

PMID:
16611012
5.

Re-evaluating the role of Frat in Wnt-signal transduction.

van Amerongen R, Berns A.

Cell Cycle. 2005 Aug;4(8):1065-72. Epub 2005 Aug 1. Review.

PMID:
16082208
6.

The role of GSK3 in glucose homeostasis and the development of insulin resistance.

Lee J, Kim MS.

Diabetes Res Clin Pract. 2007 Sep;77 Suppl 1:S49-57. Epub 2007 May 2. Review.

PMID:
17478001
7.

CK2 as a positive regulator of Wnt signalling and tumourigenesis.

Seldin DC, Landesman-Bollag E, Farago M, Currier N, Lou D, Dominguez I.

Mol Cell Biochem. 2005 Jun;274(1-2):63-7. Review.

PMID:
16342409
8.

Roles of GSK3 in metabolic shift toward abnormal anabolism in cell senescence.

Kim YM, Seo YH, Park CB, Yoon SH, Yoon G.

Ann N Y Acad Sci. 2010 Jul;1201:65-71. doi: 10.1111/j.1749-6632.2010.05617.x. Review.

PMID:
20649541
9.

Glycogen synthase kinase 3: more than a namesake.

Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A.

Br J Pharmacol. 2009 Mar;156(6):885-98. doi: 10.1111/j.1476-5381.2008.00085.x. Epub 2009 Mar 4. Review.

10.

Glycogen synthase kinase 3 in the world of cell migration.

Sun T, Rodriguez M, Kim L.

Dev Growth Differ. 2009 Dec;51(9):735-42. doi: 10.1111/j.1440-169X.2009.01141.x. Epub 2009 Nov 5. Review.

PMID:
19891643
11.

The glamour and gloom of glycogen synthase kinase-3.

Jope RS, Johnson GV.

Trends Biochem Sci. 2004 Feb;29(2):95-102. Review.

PMID:
15102436
12.

Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.

Jope RS, Roh MS.

Curr Drug Targets. 2006 Nov;7(11):1421-34. Review.

13.

GSK3 signalling in neural development.

Hur EM, Zhou FQ.

Nat Rev Neurosci. 2010 Aug;11(8):539-51. doi: 10.1038/nrn2870. Review.

14.

Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Jope RS, Yuskaitis CJ, Beurel E.

Neurochem Res. 2007 Apr-May;32(4-5):577-95. Epub 2006 Aug 30. Review.

15.

Hyperactivity: glycogen synthase kinase-3 as a therapeutic target.

Mines MA.

Eur J Pharmacol. 2013 May 15;708(1-3):56-9. doi: 10.1016/j.ejphar.2013.02.055. Epub 2013 Mar 14. Review.

PMID:
23500205

Supplemental Content

Support Center